Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic.
Cariprazine, a dopamine D3/D2 partial agonist atypical antipsychotic with preferential binding to D3 receptors, is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder.
Sumitomo Dainippon Pharma Co., Ltd. announced that topline results from a Phase III clinical study (JEWEL study, �this study�) evaluating...
The European Commission has granted Marketing Authorization for once-daily oral Latuda (lurasidone), from Takeda, for the treatment of Schizophrenia in...
The EMA's CHMP has issued a Positive Opinion for Latuda (lurasidone), from Dainippon Sumitomo Pharma and Takeda, for the treatment...
The purpose of this review is to describe the available data for brexpiprazole in the maintenance treatment of schizophrenia.
Sunovion Pharmaceuticals Inc. has announced the results of a study evaluating Latuda (lurasidone HCI) for the treatment of schizophrenia in...
Takeda announced the launch of Latuda (lurasidone), its atypical antipsychotic for the treatment of patients with schizophrenia. The launch of...
The aim of this clinical trial was to obtain proof of concept for high-dose pyridoxamine as a novel treatment for schizophrenia with enhanced carbonyl stress.
Sunovion Pharmaceuticals has announced that the FDA has approved the supplemental New Drug Application (sNDA) for Latuda (lurasidone HCI) for...